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Multisystem autoimmune disease caused by increased STAT3 phosphorylation, and 
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Francesca Todaro1,2*, Nicola Tamassia3*, Marinella Pinelli1,2, Daniele Moratto1, Laura Dotta1, 
Alessia Grassi4, Filippo Consonni1, Mauro Giacomelli1, Paolo Lionetti5, Elisa Gardiman3, Marco 
A. Cassatella3, Eleonora Gambineri4, Roberto Berni Canani6#, Raffaele Badolato1# 
 
1 Clinica Pediatrica and “A. Nocivelli” Institute for Molecular Medicine, Department of Clinical 
and Experimental Sciences, University of Brescia, Spedali Civili Hospital, Brescia, Italy. 
2 Dottorato di Ricerca in Scienze della Riproduzione e dello Sviluppo, University of Trieste, 
Trieste, Italy 
3 Department of Medicine, Division of General Pathology, University of Verona, Italy. 
4 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy 
5 Department of 'NEUROFARBA', Section of Child's Health, University of Florence and Anna 
Meyer Children's Hospital, Florence, Italy. 
6 Department of Translational Medical Science, and CEINGE Advanced Biotechnologies, and 
European Laboratory for the Investigation of Food Induced Diseases, and Task Force on 
Microbiome Investigations, University of Naples Federico II, Naples Italy 
Running title: Multisystem autoimmunity due to STAT3 mutation 
 
*FT and NT are equally contributing Authors 
#RBC and RB share senior Authorship  
 
Correspondence: Raffaele Badolato, MD, PhD, Istituto di Medicina Molecolare “Angelo Nocivelli”, 
Università di Brescia, c/o Spedali Civili, 25123 Brescia, Italy; Phone: +39 0303995717; Fax: +39 
0303388099; email: raffaele.badolato@unibs.it 
 
Total word count: 1191 
Figures: 2 
 
Acknowledgments: This work was supported in part by Ministero della Salute (grant n. NET-2013-
02355002) to RB.  
2 
 
Key point 
Multisystem autoimmunity caused by a novel heterozygous mutation of STAT3 results in 
STAT3 phosphorylation, and gene activation in resting cells. 
 
 
Case report 
 
Signal Transducer and Activator of Transcription (STAT) 3 is a member of the STAT family, 
and plays a major role in various immunological mechanisms1. Mutations in STAT3 are 
associated with a broad spectrum of manifestations including immunodeficiency, autoimmunity, 
and malignancy2. In particular, heterozygous germline Loss-Of-Function (LOF) mutations cause 
Hyper-IgE Syndrome (HIES)3–5, while heterozygous germline Gain-Of-Function (GOF) 
mutations have recently been associated to multi-organ autoimmune manifestations (i.e. type 1 
diabetes, enteropathy, cytopenia, interstitial lung disease, hypothyroidism), lymphoproliferation, 
short stature, and recurrent infections (OMIM #615952)6–8.  
 
 
 
 
We report a 7-year-old boy who presented with early-onset severe enteropathy, and diffuse 
eczematous dermatitis since birth. During the first weeks of life Hirschsprung disease was also 
suspected and surgically treated. Gastrointestinal and cutaneous manifestations were first 
ascribed to food allergy with a quite good response to amino acid-based formula. In the 
following months, the patient developed failure to thrive, and respiratory tract infections. At two 
years, the patient presented with progressive interstitial lung disease, characterized by 
lymphocytic interstitial infiltration leading to pulmonary hypertension, tricuspid insufficiency, 
and right ventricular heart failure with hepatomegaly. Because of the increased risk of infections, 
he received IV immunoglobulin infusions (400 mg/kg), prophylaxis with cotrimoxazole and 
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fluconazole. Methylprednisolone at 0.3 mg/kg/day was also given to treat autoimmune 
manifestations. 
 At later times, growth hormone (GH) deficiency, hypothyroidism and type 1 diabetes were 
diagnosed.  
 
Informed consent was obtained from parents of the patient. Ethical approval was obtained by the 
Institutional Review Board of Spedali Civili of Brescia. Genomic DNA was extracted from 
peripheral whole blood, Whole Exome Sequencing (WES) was performed while the identified 
mutation was validated by Sanger sequencing5. STAT3 phosphorylation was analyzed by flow 
cytometry on whole blood after stimulation with interferon (IFN)-α (40,000 U/ml) or interleukin 
(IL)-27 (100ng/mL) for 30’ according to BD protocol: cells were acquired using FACSCalibur 
(BD Bioscence) and analyzed by FlowJo version 7.5 Software (TreeStar). Epstein-Barr virus 
(EBV)-immortalized B cells Western Blot assay was performed after overnight starvation as 
previously described5. 
Reverse transcription quantitative real-time PCR (RT-qPCR) was performed with specific probes 
(Applied Biosystems) on CFX96 RT System (BIO-RAD). EBV cells were stimulated with 
200ng/mL of IL-6 or IL-10 for 1 hour with/without overnight starvation. Results are shown as 
mean normalized expression (MNE) units after GAPDH normalization. 
Chromatin immunoprecipitation (ChIP) assay was performed on 5x106 EBV-transformed cell 
lines stimulated with IL-10 or IL-6 for 45’ and executed as described9. To establish the 
background levels of ChIP experiments, STAT3 was quantified also at the promoter of prolactin 
(PRL) since it is completely silent in leukocytes. Additional details can be provided upon 
request. 
Data Sharing Statement: For original data, please contact raffaele.badolato@unibs.it 
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Because of the association of severe early-onset enteropathy and autoimmune manifestations, 
Immunodeficiency Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome or other IPEX-
like inherited disorders were suspected. But the search for mutations in FOXP3, CD25 and 
STAT5b resulted negative 10,11. Subsequently, WES was performed and a de novo heterozygous 
missense STAT3 mutation was identified that clustered in the DNA-binding domain and caused 
methionine-to-arginine substitution (c.1986T>G) at position 329 (p.M329R). Lymphocyte 
subsets analysis revealed normal levels of regulatory (CD4+ CD25hi FOXP3+) and effector 
(CD45RA-CCR7-) CD3+ T lymphocytes. 
STAT3 activation in response to cytokines such as IL-6, IL-10, IL-21, IL-23 and IFN-α is 
characterized by phosphorylation of tyrosine 705 (pY705) by associated Janus activating kinases 
(JAKs) and subsequent STAT–STAT dimerization and nucleus translocation12. We 
comparatively evaluated by ELISA assay plasmatic cytokines concentration in the patient and in 
age-matched healthy donors. Detectable levels of IL-6 (72.04 pg/ml) , IL-10 (32.5 pg/ml) and 
IL-17(55.82 pg/ml) were observed in the patient, but not in the healthy donors (data not shown). 
The flow cytometry analysis of CD3+ lymphocytes showed detectable levels of STAT3 
phosphorylation (pSTAT3) in the patient, but not in healthy donors. Increased pSTAT3 levels 
were observed both in unstimulated conditions and after IFN-α or IL-27 stimulation (Figure 1a). 
Next, we analyzed STAT3 phosphorylation in unstimulated cells or after 15, 30, 60, 90 and 120 
minutes after stimulation of EBV-transformed cell lines with IFN-α (20000U/mL). The patient 
showed a delayed dephosphorylation of STAT3, especially 90’ after stimulation (Figure 1b).  
Finally, we investigated the levels of pSTAT3 by Western Blot assay in unstimulated cells, and 
following IL-6 or IL-10 stimulation in EBV-transformed cell lines. Analysis of cells derived 
from the patient with GOF mutation showed detectable levels of pSTAT3 also in unstimulated 
conditions, which increased after IL-6 (200ng/mL) or IL-10 (200ng/mL) stimulation. This was 
associated with increased levels of STAT3 protein as compared to the healthy subjects (Figure 
1c).  
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In order to evaluate STAT3 binding capacity to specific DNA sequences involved in the 
regulation of inflammation and immune response (e.g. SOCS3 and SNBO2), we performed a 
chromatin immunoprecipitation (ChIP) assay in EBV-transformed cells from the patient with 
STAT3 GOF mutation and from a healthy subject. We observed that unstimulated cells from the 
patient showed enhanced STAT3 binding to SOCS3 and SBNO2 promoters. But, after 
stimulation with IL-6 or IL-10, STAT3 binding was weakly increased as compared to cells from 
healthy controls (Figure 1d).  
Moreover, we evaluated the expression of STAT3, IL-10, BCL-3, IL2RA and SOCS3 mRNAs 
by -RT-qPCR. Analysis of mRNAs in unstimulated cells from the patient showed high level 
expression of STAT3, IL-10, BCL-3, IL2RA, and SOCS3 at baseline, and further increase of 
SOCS3 and IL10 mRNAs after stimulation with IL-6 or IL-10. While, cell starvation did not 
influence the extent of gene expression in the cells of the patient (Figure 2a-e). 
 
Patients with GOF-STAT3 mutation share similar phenotypic manifestations (i.e. eczema, 
autoimmunity) with STAT5b deficient patients13, suggesting that STATs proteins 
phosphorylation and expression can be negatively regulated by STAT3-mediated induction of 
SOCS3 14. Therefore, we investigated cytokine-induced phosphorylation of both STAT1 and 
STAT2, and the expression of the total amount of STAT1 protein in the EBV-transformed cell 
line from the patient with STAT3 GOF mutation and from a healthy subject. 
After preparation of cytoplasmic extracts, we observed that STAT2 phosphorylation levels were 
lower in STAT3-mutated cells after IFNα stimulation, as compared to healthy control. In 
contrast, the level of phosphorylated and total STAT1 was similar in both control and patient 
EBV-transformed cell lines. (Figure 2f). These results suggest that the STAT3 GOF mutation 
p.M329R affect not only STAT3, but also STAT2 mediated-response.  
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Immunological studies in this patient revealed normal T cell subsets, but severe depletion of both 
plasmacytoid (BDCA2+/CD123+/CD4+) and myeloid dendritic (CD1c+/CD4+/CD19-/CD14-) 
cells: pDC 0.06%, mDC 0.05% of total PBMC as compared to healthy subjects (pDC n.v. 0.16-
0.7%, mDC n.v. 0.18-0.92%). This is in contrast with two other cases that showed increased T 
effector cell counts and a reduction of T regulatory cells 1,15, but these differences might be 
related to inter-individual variations.  Moreover, high plasmatic concentrations of IL-6, IL-10 
and IL-17 in this patient were also observed, suggesting that these cytokines might be involved 
in the mechanism of the autoimmune diseases. All these atypical immunological features are 
probably related to the novel STAT3 mutation which was associated with increased 
phosphorylation of STAT3. While most of patients with STAT3 GOF mutations display normal 
STAT3 phosphorylation, but abnormal gene regulation7.  
Current therapeutic of multiple organ autoimmune diseases in patients with STAT3 GOF 
mutations  include immunosuppressive drugs, and hematopoietic stem cell transplantation in 
selected patients16. Because tyrosine kinases inhibitors, such as ruxolitinib, have been 
extensively used in conditions characterized by abnormal STAT activation, their use could be 
favorably extended to immunological diseases  associated with increased STAT3 
phosphorylation such as observed in this case17.   
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Figure Legends 
 
Figure 1. STAT3 phosphorylation and chromatin immunoprecipitation assay in the STAT3 
GOF patient . 
(A) STAT3 phosphorylation in T cells (CD3+ cells) in response to IFNα and IL-27 stimulation 
or medium alone. Cells from whole blood samples were lysed, fixed and permeabilized, then 
stained with anti-p-STAT3 and anti-CD3 antibodies. Extent of p-STAT3 is shown on y- axis as 
mean fluorescent intensity. (B) Time course of STAT3 phosphorylation of EBV-transformed B 
cell lines obtained from a control subject or from the STAT3 GOF patient. Cells were kept in 
culture with serum free medium over-night and stimulated with IFNα for 15, 30, 60, 90 or 120 
minutes. Then, cells were permeabilized and stained with anti-p-STAT3. Extent of p-STAT3 is 
shown on y-axis as mean fluorescent intensity. (C) Western Blot analysis of STAT3 tyrosine 
phosphorylation in EBV-transformed B cell lines from a control subject or from the STAT3 
GOF patient. Cells were kept in culture with serum free medium overnight and then either 
untreated or stimulated with IL-6 (200 ng/mL) and IL-10 (200 ng/mL) for 30 minutes.(D) 
Evaluation, by ChIP analysis, of STAT3 recruitment to the SOCS3, SBNO2, IL-10 and PRL 
promoters of EBV-transformed B cells cultured in the presence or absence of IL-6 (200ng/mL) 
and IL-10 (200ng/mL) for up to 1 h. Co-immunoprecipitated DNA was expressed as percent of 
the total input. Error bars represent standard errors calculated from triplicate qPCR reactions. 
 
 
Figure 2 Analysis STAT3, IL10, BCL3, IL2RA, and SOCS3 mRNAs expression in EBV-
transformed B cell lines 
A-E) EBV-transformed B cell lines from 2 healthy donors or the STAT3 GOF patient were kept 
overnight in serum-free medium and then either untreated or stimulated for 1 hour with IL-6 
(200ng/mL) and IL-10 (200ng/mL) to investigate STAT3, IL10, BCL3, IL2RA, and SOCS3 
mRNAs by RT-qPCR. F) Western Blot analysis of STAT1 and STAT2 levels in cytoplasmic 
extracts from EBV-transformed B cells from a control subject or the STAT3 GOF patient. Cells 
were cultured overnight without serum and then stimulated with IFNα (1000 U/ml) for 30 min. 
Levels of p-STAT1, p-STAT2, total STAT1 and STAT2 in the cytoplasmic fractions were 
evaluated. Samples were also immunoblotted for tubulin, a cytoplasmic marker. 
 


